Estimated at USD 428 million in 2025, the Veterinary Urinalysis Product market size is projected to reach USD 672 million by 2033, underpinned by a 6.2% CAGR over the forecast window. North America retains the largest revenue share (≈41%) on dense pet ownership and high procedure reimbursement, while Asia-Pacific emerges as the fastest-expanding region (>8% CAGR) on rising pet insurance penetration and clinic consolidation in China and India. Macro drivers include the 60% surge in chronic feline lower-urinary-tract disorders, integration of AI-driven sediment recognition that cuts manual review time by 45%, and tightening AAHA/EFSA guidelines that now recommend annual urinalysis for animals >7 years. Competitive intensity is sharpening as human-diagnostics leaders (e.g., Siemens Healthineers, Roche) extend hematology platforms into veterinary settings, compressing traditional 5-minute strip read-times to <90 seconds and shifting margin pressure toward mid-tier players. Simultaneously, supply-chain volatility in nitrite and pH reagents is prompting Tier-1 suppliers to dual-source chemistries and raise safety-stock targets from 30 to 60 days, a move expected to normalize COGS inflation by 2H 2026.